Top

Published in:

01-03-2016 | Letter to the Editor

Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma

Authors: Pasquale L. Fedele, Gareth P. Gregory, Michael Gilbertson, Jake Shortt, Beena Kumar, Stephen Opat, George Grigoriadis

Published in: Annals of Hematology | Issue 4/2016

Excerpt

Dear Editor, …

Wilson WH (2002) Dose adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99(8):2685–2693. doi:10.1182/blood.V99.8.2685 CrossRefPubMed

Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED, Cancer Leukemia Group B (2012) A Cancer and Leukemia Group B multi center study of DA EPOCH rituximab in untreated diffuse large B cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5):758–765. doi:10.3324/haematol.2011.056531 CrossRefPubMedPubMedCentral

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood 113(24):6069–6076. doi:10.1182/blood-‐2009-‐01-‐199679 CrossRefPubMedPubMedCentral

Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM (2015) The generation of antibody secreting plasma cells. Nat Rev Immunol 15(3):160–171. doi:10.1038/nri3795 CrossRefPubMed

Montes Moreno S, Gonzalez Medina AR, Rodriguez-‐Pinilla SM, Maestre L, Sanchez Verde L, Roncador G, Mollejo M, Garcia JF, Menarguez J, Montalban C, Ruiz Marcellan MC, Conde E, Piris MA (2010) Aggressive large B cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B cell lymphoma with partial plasmablastic phenotype. Haematologica 95(8):1342–1349. doi:10.3324/haematol.2009.016113 CrossRefPubMedPubMedCentral

Castillo JJ, Reagan JL (2011) Plasmablastic lymphoma: a systematic review. Sci World J 11:687–696. doi:10.1100/tsw.2011.59 CrossRef

Ling SC, Lau EK, Al-‐Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD (2012) Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 97(1):64–72. doi:10.3324/haematol.2011.043331 CrossRefPubMedPubMedCentral

Leung Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE (2013) Xbp1s negative tumor B cells and pre plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24(3):289–304. doi:10.1016/j.ccr.2013.08.009 CrossRefPubMedPubMedCentral

Taubenheim N, Tarlinton DM, Crawford S, Corcoran LM, Hodgkin PD, Nutt SL (2012) High rate of antibody secretion is not integral to plasma cell differentiation as revealed by XBP-1 deficiency. J Immunol 189(7):3328–3338. doi:10.4049/jimmunol.1201042 CrossRefPubMed

10.

Castillo JJ, Reagan JL, Sikov WM, Winer ES (2015) Bortezomib in combination with infusional dose adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. doi:10.1111/bjh.13300

Title: Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma
Authors: Pasquale L. Fedele
Gareth P. Gregory
Michael Gilbertson
Jake Shortt
Beena Kumar
Stephen Opat
George Grigoriadis
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 4/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2601-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2016

Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone

Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study

Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab

Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification

Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma

Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page